Imprimis Phar Cmn (IMMY) 3.82 $IMMY
Following Congressional Hearing Investigating Mylan and Epi-Pen, Imprimis Pharmaceuticals Founder and CEO Publishes Drug Pricing Monograph
PR Newswire - Thu Sep 22, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable through its Branded Compounding(TM) business model, published a 75-page well-referenced drug pricing monograph describing specific proposals that will drive competition, transparency and patient access by lowering drug costs for Americans.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations
PR Newswire - Tue Sep 06, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable through its Branded Compounding(TM) business model, today announced the launch of the Imprimis Cares Access Network (ICAN), a new patient assistance program designed to simplify the process of accessing Imprimis' patent-pending Tiopronin Delayed Release (Tiopronin-DR) compounded formulations, a lower cost alternative to Thiola®, as well as other Imprimis Cares® compounded formulations.
IMMY: 3.82 (-0.05)
Investor Calendar Invites You to the Imprimis Pharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016
ACCESSWIRE - Mon Aug 15, 8:02AM CDT
SAN DIEGO, CA / ACCESSWIRE / August 15, 2016 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Monday, August 15, 2016 at 4:30 PM Eastern Time.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in Operations, Quality, Manufacturing and Client Relations
PR Newswire - Mon Aug 15, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported the expansion of its leadership team with the appointments of Clayton Edwards as Senior Vice President of Operations, Eric Rice as Vice President of Client Relations, Pramod Sharma, PhD as Vice President of Quality, and Sanjay Samudre as Director of Manufacturing.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Announces $2 Million Equipment Sale Leaseback Agreement with Essex Capital Corporation
PR Newswire - Thu Aug 11, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced it has entered in an equipment lease agreement with Essex Capital Corporation which provided Imprimis with gross proceeds of $2.0 million at closing. The agreement covers the sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years, with an additional one-year lease extension, subject to Imprimis achieving certain financial milestones.
IMMY: 3.82 (-0.05)
Medical Product Stock Earnings Coming Up: IMMY, OMCM, CLRB
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 6:50AM CDT
For the rest of the season, earnings are anticipated to grow 4.7%, driven by impressive top-line growth expectation of 7.7% in Medical sector.
CLRB: 2.74 (-0.04), IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Host its Second Quarter 2016 Financial Report Conference Call and Webcast on August 15, 2016 at 4:30 p.m. EDT
PR Newswire - Mon Aug 01, 8:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported it will release second quarter 2016 financial results after the close of trading on Monday, August 15, 2016. The company will host a conference call at 4:30 p.m. EDT/1:30 p.m. PDT on the same day to discuss the financial results and recent business developments.
IMMY: 3.82 (-0.05)
Imprimis Launches New MaxRx Prescriber Portal(TM)
PR Newswire - Fri Jul 29, 8:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced the availability of its new MaxRx Prescriber Portal(TM), a software application that provides physicians with new order entry and management tools that have traditionally not been available for compounded prescriptions. In addition to allowing a streamlined ordering process for single and multiple orders, MaxRx has numerous other functions designed to give the prescriber maximum visibility into order workflow, and maximum flexibility in communicating and doing business with an ImprimisRx pharmacy.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Present at 6th Annual LD Micro Invitational on June 8, 2016
PR Newswire - Fri Jun 03, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Financial Officer, Andrew R. Boll, will present an update on the company's business at the 6th Annual LD Micro Invitational on Wednesday, June 8, 2016 at 2:00 p.m. (PDT) in Bel Air, Calif. Imprimis will also be hosting one-on-one meetings and attendees can contact their LD Micro representative to arrange a meeting.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. (EDT) in New York City, NY. The presentation will be broadcast in a live webcast and an archive of the webcast will be available for 90 days following the event. Access will be available at http://wsw.com/webcast/jeff97/immy or on the Investor Relations section of Imprimis' website at www.ImprimisPharma.com. Imprimis will also be hosting one-on-one meetings and attendees can contact their Jefferies representative to arrange a meeting.
IMMY: 3.82 (-0.05)
Imprimis reports 1Q loss
Automated Insights - Thu May 12, 3:31PM CDT
SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $4.5 million in its first quarter.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Thu May 12, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported financial results for the first quarter 2016, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Announces Plans to Launch IV Free(TM) Conscious Sedation and New Compounded Triple Drop Formulations at Leading Cataract and Refractive Surgeons Meeting
PR Newswire - Thu May 05, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free(TM) MKO Melt(TM) conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Host its First Quarter 2016 Financial Report Conference Call and Webcast on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Wed May 04, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its first quarter 2016 financial results on Thursday, May 12, 2016. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola®
PR Newswire - Mon May 02, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced the availability of the company's new patent-pending customizable delayed-release (DR) tiopronin formulations as a lower-cost therapeutic alternative to FDA-approved Thiola®. Thiola, FDA-approved as a 100mg tablet, is composed of tiopronin as its sole active drug ingredient and is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. Physicians and their cystinuria patients may now choose from one of two lower-cost compounded alternatives to Thiola.
IMMY: 3.82 (-0.05)
Statement on Imprimis Pharmaceuticals' Announcement Regarding Thiola(R)
GlobeNewswire - Wed Feb 10, 12:28PM CST
Retrophin, Inc. (NASDAQ:RTRX) has issued the following statement in response to Imprimis Pharmaceuticals' announcement of its intention to make a compounded alternative to Thiola:
RTRX: 22.57 (-0.70), IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola®
PR Newswire - Wed Feb 10, 8:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced plans to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations that may be prescribed by physicians as a lower cost therapeutic alternative to FDA-approved Thiola. The formulations are expected to be available to prescribers in April 2016. Thiola, made of tiopronin as its active drug ingredient, is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. According to the National Organization for Rare Disorders, in addition to chelating medications such as tiopronin, potassium citrate is often co-prescribed and taken separately to make the urine more alkaline, potentially reducing cystine crystallization and stone formation.
IMMY: 3.82 (-0.05)
Express Scripts Provides Better-than-Expected 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:40PM CST
Express Scripts Holding Company (ESRX) has issued an encouraging guidance for 2016.
ANTM: 126.56 (-1.86), ESRX: 71.34 (+0.31), UNH: 140.51 (-0.53), IMMY: 3.82 (-0.05)
Global Peyronies Disease Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcx4vk/peyronies_disease) has announced the addition of the "Peyronies Disease Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Peyronies Disease Global Clinical Trials Review, H2, 2015" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Endo International Plc - Dimensione Ricerca S.r.l. (Inactive) - Allergan Plc - TFS International AB - Men's Health Boston - Imprimis Pharmaceuticals, Inc. - Hybrid Medical, LLC For more information visit http://www.researchandmarkets.com/research/zc...es_disease
AGN: 243.94 (+0.51), IMMY: 3.82 (-0.05)
Following Congressional Hearing Investigating Mylan and Epi-Pen, Imprimis Pharmaceuticals Founder and CEO Publishes Drug Pricing Monograph
PR Newswire - Thu Sep 22, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable through its Branded Compounding(TM) business model, published a 75-page well-referenced drug pricing monograph describing specific proposals that will drive competition, transparency and patient access by lowering drug costs for Americans.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations
PR Newswire - Tue Sep 06, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable through its Branded Compounding(TM) business model, today announced the launch of the Imprimis Cares Access Network (ICAN), a new patient assistance program designed to simplify the process of accessing Imprimis' patent-pending Tiopronin Delayed Release (Tiopronin-DR) compounded formulations, a lower cost alternative to Thiola®, as well as other Imprimis Cares® compounded formulations.
IMMY: 3.82 (-0.05)
Investor Calendar Invites You to the Imprimis Pharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016
ACCESSWIRE - Mon Aug 15, 8:02AM CDT
SAN DIEGO, CA / ACCESSWIRE / August 15, 2016 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Monday, August 15, 2016 at 4:30 PM Eastern Time.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in Operations, Quality, Manufacturing and Client Relations
PR Newswire - Mon Aug 15, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported the expansion of its leadership team with the appointments of Clayton Edwards as Senior Vice President of Operations, Eric Rice as Vice President of Client Relations, Pramod Sharma, PhD as Vice President of Quality, and Sanjay Samudre as Director of Manufacturing.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Announces $2 Million Equipment Sale Leaseback Agreement with Essex Capital Corporation
PR Newswire - Thu Aug 11, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced it has entered in an equipment lease agreement with Essex Capital Corporation which provided Imprimis with gross proceeds of $2.0 million at closing. The agreement covers the sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years, with an additional one-year lease extension, subject to Imprimis achieving certain financial milestones.
IMMY: 3.82 (-0.05)
Medical Product Stock Earnings Coming Up: IMMY, OMCM, CLRB
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 6:50AM CDT
For the rest of the season, earnings are anticipated to grow 4.7%, driven by impressive top-line growth expectation of 7.7% in Medical sector.
CLRB: 2.74 (-0.04), IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Host its Second Quarter 2016 Financial Report Conference Call and Webcast on August 15, 2016 at 4:30 p.m. EDT
PR Newswire - Mon Aug 01, 8:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported it will release second quarter 2016 financial results after the close of trading on Monday, August 15, 2016. The company will host a conference call at 4:30 p.m. EDT/1:30 p.m. PDT on the same day to discuss the financial results and recent business developments.
IMMY: 3.82 (-0.05)
Imprimis Launches New MaxRx Prescriber Portal(TM)
PR Newswire - Fri Jul 29, 8:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced the availability of its new MaxRx Prescriber Portal(TM), a software application that provides physicians with new order entry and management tools that have traditionally not been available for compounded prescriptions. In addition to allowing a streamlined ordering process for single and multiple orders, MaxRx has numerous other functions designed to give the prescriber maximum visibility into order workflow, and maximum flexibility in communicating and doing business with an ImprimisRx pharmacy.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Present at 6th Annual LD Micro Invitational on June 8, 2016
PR Newswire - Fri Jun 03, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Financial Officer, Andrew R. Boll, will present an update on the company's business at the 6th Annual LD Micro Invitational on Wednesday, June 8, 2016 at 2:00 p.m. (PDT) in Bel Air, Calif. Imprimis will also be hosting one-on-one meetings and attendees can contact their LD Micro representative to arrange a meeting.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. (EDT) in New York City, NY. The presentation will be broadcast in a live webcast and an archive of the webcast will be available for 90 days following the event. Access will be available at http://wsw.com/webcast/jeff97/immy or on the Investor Relations section of Imprimis' website at www.ImprimisPharma.com. Imprimis will also be hosting one-on-one meetings and attendees can contact their Jefferies representative to arrange a meeting.
IMMY: 3.82 (-0.05)
Imprimis reports 1Q loss
Automated Insights - Thu May 12, 3:31PM CDT
SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $4.5 million in its first quarter.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Thu May 12, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported financial results for the first quarter 2016, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Announces Plans to Launch IV Free(TM) Conscious Sedation and New Compounded Triple Drop Formulations at Leading Cataract and Refractive Surgeons Meeting
PR Newswire - Thu May 05, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free(TM) MKO Melt(TM) conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Host its First Quarter 2016 Financial Report Conference Call and Webcast on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Wed May 04, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its first quarter 2016 financial results on Thursday, May 12, 2016. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola®
PR Newswire - Mon May 02, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced the availability of the company's new patent-pending customizable delayed-release (DR) tiopronin formulations as a lower-cost therapeutic alternative to FDA-approved Thiola®. Thiola, FDA-approved as a 100mg tablet, is composed of tiopronin as its sole active drug ingredient and is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. Physicians and their cystinuria patients may now choose from one of two lower-cost compounded alternatives to Thiola.
IMMY: 3.82 (-0.05)
Statement on Imprimis Pharmaceuticals' Announcement Regarding Thiola(R)
GlobeNewswire - Wed Feb 10, 12:28PM CST
Retrophin, Inc. (NASDAQ:RTRX) has issued the following statement in response to Imprimis Pharmaceuticals' announcement of its intention to make a compounded alternative to Thiola:
RTRX: 22.57 (-0.70), IMMY: 3.82 (-0.05)
Imprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola®
PR Newswire - Wed Feb 10, 8:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced plans to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations that may be prescribed by physicians as a lower cost therapeutic alternative to FDA-approved Thiola. The formulations are expected to be available to prescribers in April 2016. Thiola, made of tiopronin as its active drug ingredient, is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. According to the National Organization for Rare Disorders, in addition to chelating medications such as tiopronin, potassium citrate is often co-prescribed and taken separately to make the urine more alkaline, potentially reducing cystine crystallization and stone formation.
IMMY: 3.82 (-0.05)
Express Scripts Provides Better-than-Expected 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:40PM CST
Express Scripts Holding Company (ESRX) has issued an encouraging guidance for 2016.
ANTM: 126.56 (-1.86), ESRX: 71.34 (+0.31), UNH: 140.51 (-0.53), IMMY: 3.82 (-0.05)
Global Peyronies Disease Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcx4vk/peyronies_disease) has announced the addition of the "Peyronies Disease Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Peyronies Disease Global Clinical Trials Review, H2, 2015" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Endo International Plc - Dimensione Ricerca S.r.l. (Inactive) - Allergan Plc - TFS International AB - Men's Health Boston - Imprimis Pharmaceuticals, Inc. - Hybrid Medical, LLC For more information visit http://www.researchandmarkets.com/research/zc...es_disease
AGN: 243.94 (+0.51), IMMY: 3.82 (-0.05)
